Drugs / Exenatide SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03961256 | May 2019 → Oct 2021 | prediabetes syndrome | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exenatide SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03961256 ↗ |
| Route | Subcutaneous | “Exenatide SR 2 mg subcutaneous (SQ) weekly” NCT03961256 ↗ |